Charles Gayer
Vermogen: 4 M $ op 30-06-2026
Vermogen: 4 M $ op 30-06-2026
Charles K.
Gayer is President, Chief Executive Officer & Director at BioCryst Pharmaceuticals, Inc. since 2026.
Formerly, Mr. Gayer was Head-US & Global Commercial Business at Grifols Therapeutics, Inc. Education includes an undergraduate degree from Princeton University and an MBA from The Fuqua School of Business.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-04-2026 | 364.620 ( 0,14% ) | 4 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Algemeen Directeur | 01-01-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Health Technology |
The Fuqua School of Business
The Fuqua School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau